The deal size was increased to $175M in common stock from $150M in common stock and priced within the $84.00-$89.00 range. Morgan Stanley, BofA, Stifel and Wells Fargo acted as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals prices 2.06M shares at $85.00 in upsized public offering
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA
- Rhythm Pharmaceuticals resumed with a Buy at Goldman Sachs
- Rhythm Pharmaceuticals Reports Positive Phase 2 Trial Results